Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options

Laurie Elit, Hal Hirte, Laurie Elit, Hal Hirte

Abstract

Objectives: To review the available systemic treatments for women with recurrent ovarian cancer.

Methods: A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews.

Results: We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer. Clearly, platinum-based combination systemic therapy shows a prolonged progression-free interval compared with single-agent chemotherapy with a low toxicity profile. No clear superior management strategy exists for platinum-resistant/refractory disease. Novel targeted antiangiogenic agents (eg, bevacizumab), angiopoeitin inhibitors (eg, AMG 386), and poly ADP ribose polymerase inhibitors (eg, olaparib) are reviewed.

Conclusion: Although combination platinum-based chemotherapy has shown benefits for women with platinum-sensitive recurrent ovarian cancer, the optimal treatment strategy for those with platinum-resistant or platinum-refractory disease is not clear. Molecular and genetic targeted therapies may provide opportunities for those women with tumor profiles that show sensitivity for specific agents.

Keywords: biologic agents; ovarian cancer; systemic therapy.

References

    1. Canadian Cancer Society’s Steering Committee on Cancer Statistics Canadian Cancer Statistics 2012 Toronto, ON: Canadian Cancer Society; 2012Available from: Accessed September 15, 2012
    1. Fleming GF, Ronnett BM, Seidman J, Zaino RJ, Rubin SC. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, editors. Principles and Practice of Gynecologic Oncology. Philadelphia: Wolters Kluwer Health, Lippincott Williams & Wilkins; 2009. pp. 763–854.
    1. Ozols RF, Bundy BN, Greer BE, et al. Gynecology Oncology Group Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–3200.
    1. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9(3):389–393.
    1. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments] Ann Oncol. 1997;8(10):963–968.
    1. Markman M, Markman J, Webster K, et al. Duration of response to second-line platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22(15):3120–3125.
    1. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9(3):167–181.
    1. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14(5):195–208.
    1. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15(6):2183–2193.
    1. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312–3322.
    1. Parmar MK, Ledermann JA, Colombo N, et al; ICON, AGO Collaborators Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099–2106.
    1. González-Martín AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol. 2005;16(5):749–755.
    1. Pfisterer J, Plante M, Vergote I, et al; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–4707.
    1. Bolis G, Scarfone G, Giardina G, et al. Associazione per Ricerca in Ginecologia Oncologia (ARGO 96) Study Group Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol. 2001;81(1):3–9.
    1. Cantú MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to firstline platinum-based regimens. J Clin Oncol. 2002;20(5):1232–1237.
    1. Alberts DS, Liu PY, Wilczynski SP, et al. Southwest Oncology Group Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwestern Oncology Group Protocol S02000) Gynecol Oncol. 2008;108(1):90–94.
    1. Markman M, Moon J, Wilczynski S, et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol. 2010;116(3):323–325.
    1. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28(19):3107–3114.
    1. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323–3329.
    1. Fung Kee Fung M, Kennedy E, Francis J, Mackay H, members of the Gynecologic Cancer Disease Site Group Optimal Chemotherapy for Recurrent Ovarian Cancer Toronto, ON: Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO)2011Available from: Accessed December 10, 2012
    1. Katsumata N, Yasuda M, Takahashi F, et al. Japanese Gynecologic Oncology Group Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331–1338.
    1. North Eastern Germany Society of Gynecologic Oncology Hycamtin Plus carboplatinum versus established regimens for the treatment of ovarian cancer relapse ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2011[updated August 26, 2011]. Available from: NLM identifier: HECTOR. Accessed December 20, 2012
    1. Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study 30-49 Investigators Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95(1):1–8.
    1. ten Bokkel Huinink W, Lane SR, Ross GA, International Topotecan Study Group Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol. 2004;15(1):100–103.
    1. O’Byrne KJ, Bliss P, Graham JD, Gerber J, Vasey PA, Khanna S. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer [ASCO abstract 808] Proceedings American Society of Clinical Oncology. 2002;21:203a.
    1. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer. 2002;38(1):57–63.
    1. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25(19):2811–2818.
    1. Bolis G, Parazzini F, Scarfone G, et al. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol. 1999;72(1):60–64.
    1. Torri V, Floriani I, Tinazzi A, et al. Randomized trial comparing paclitaxel + doxorubincin (AT) versus paclitaxel (T) as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum based chemotherapy [ASCO abstract 1506] Proceedings of the American Society of Clinical Oncology. 2000;19:381a.
    1. Buda A, Floriani I, Rossi R, et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the ‘Mario Negri’ Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group. Br J Cancer. 2004;90(11):2112–2117.
    1. Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176–3182.
    1. Lortholary A, Largillier R, Weber B, et al. GINECO group France Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO) Ann Oncol. 2012;23(2):346–352.
    1. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol. 2005;23(9):1867–1874.
    1. Smit WM, Šufiarsky J, Spanik S, et al. Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer [ASCO abstract 5056] J Clin Oncol. 2005;23(16S):5056.
    1. Colombo N, Schwartz PE, Bamias A. Results of a randomized, open-label, phase 3 trial of patupilone (P) versus pegylated liposomal doxorubicin (PLD) in taxane/platinum refractory/resistant patients with recurrent ovarian, fallopian or peritoneal cancer; Proceedings of the 35th European Society for Medical Oncology Congress [abstract 4843]; October 8–12, 2010; Milan, Italy.
    1. Hirte H W. Novel developments in angiogenesis cancer therapy. Curr Oncol. 2009;16(3):50–54.
    1. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165–5171.
    1. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26(1):76–82.
    1. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II Study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180–5186.
    1. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [ASCO abstract LBA5002] J Clin Oncol. 2012;30(S18):LBA5002.
    1. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.
    1. Itamochi H, Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol. 2012;17(5):430–440.
    1. Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study [ASCO abstract 5508] J Clin Oncol. 2007;25(S18):5508.
    1. Gotlieb WH, Amant F, Advani S, et al. Intravenous afibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154–162.
    1. Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of PMH, Chicago and California consortia Trial [ASCO abstract 5521] J Clin Oncol. 2008;26:5521.
    1. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascularendothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601–5606.
    1. Boehringer Ingelheim Pharmaceuticals A randomized placebo-controlled Phase 2 study of continuous maintenance treatment with BIBF1120 following chemotherapy in patients with relapsed ovarian cancer ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2011[updated August 26, 2011]. Available from: NLM identifier: NCT00710762. Accessed December 20, 2012
    1. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29(28):3798–3804.
    1. Matei D, Sill MW, DeGeest K, Bristow RE. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer; a Gynaecologic Oncology Group Study [ASCO abstract 5537] J Clin Oncol. 2008;26:5537.
    1. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26(22):3709–3714.
    1. Welch S, Hirte H, Elit L, et al. CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcit-abine and sorafenib: A trial of the PMH Phase II Consortium [ASCO abstract 5519] J Clin Oncol. 2007;25(Suppl 18S):5519.
    1. Charite University, Berlin, Germany Efficacy and safety study of sorafenib with Topotecan in patients with platinum resistant recurrent ovarian cancer ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2011[updated August 26, 2011]. Available from: NLM identifier: NCT 01047891. Accessed December 20, 2012
    1. NCI Sorafenib with or without paclitaxel and carboplatin in treating patients with recurrent ovarian cancer, primary peritoneal cancer or fallopian tube cancer ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2011[updated August 26, 2011]. Available from: NLM identifier: NCT00096200. Accessed December 20, 2012
    1. Biagi JJ, Oza AM, Chalchal HI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol. 2011;22(2):335–340.
    1. Baumann KH, du Bois A, Meier W, et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol. 2012;23(9):2265–2271.
    1. Campos SM, Penson RT, Matulonis U, et al. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2012 Aug 9; Pii: S0090-8258(12)00652-X.
    1. Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32–37.
    1. Oaknin A, Gonzalez-Martin A, García Y, et al. A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or fallopian tube cancer (FTC): a Spanish Ovarian Cancer Group (GEICO) study [ASCO abstract 5068] J Clin Oncol. 2012;30:5068.
    1. Buckanovich RJ, Berger R, Sella A, et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT) [ASCO abstract 5008] J Clin Oncol. 2011;29:5008.
    1. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30(4):362–371.
    1. AMGEN TRINOVA-1 A study of AMG386 or placebo in combination with weekly paclitaxel chemotherapy as treatment for ovarian cancer, primary peritoneal cancer and fallopian tube cancer Bethesda, MD: US National Library of Medicine; 2011[updated August 26, 2011]. Available from: NLM identifier:TRINOVA-1. Accessed December 20, 2012
    1. AMGEN TRINOVA-2 TRial IN OVArian cancer Bethesda, MD: US National Library of Medicine; 2011[updated August 26, 2011]. Available from: NLM identifier: TRINOVA-2. Accessed December 20, 2012
    1. Siwak DR, Carey M, Hennessy BT, et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol. 2010;2010:568938.
    1. Zeineldin R, Muller CY, Stack MS, Hudson LG. Targeting the EGF receptor for ovarian cancer therapy. J Oncol. 2010;414676
    1. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer. 2011;104(8):1241–1254.
    1. Posadas EM, Kwitkowski V, Kotz HL, et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007;110(2):309–317.
    1. Jelovac D, Armstrong DK. Role of farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des. 2012;18(25):3812–3815.
    1. Morphotek An efficacy and safety study of MORAb-003 in platinum-resistant or refractory relapsed ovarian cancer Bethesda, MD: US National Library of Medicine; 2011[updated August 26, 2011]. Available from: NLMidentifier: FAR-122. Accessed December 20, 2012
    1. Naumann RW, Symanowski JT, Ghamande SA, et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer [ASCO abstract LBA5012b] J Clin Oncol. 2010;28(S18):LBA5012b.
    1. ENDOCYTE Study for women with platinum resistant ovarian cancer evaluating EC145 in combination with Doxil® Bethesda, MD: US National Library of Medicine; 2011[updated August 26, 2011]. Available from: NLM identifier: NCT01170650. Accessed December 20, 2012
    1. Dantzer F, de La Rubia G, Ménissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry. 2000;29(25):7559–7569.
    1. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer [ASCO abstract 5500] J Clin Oncol. 2009;27(S15):5500.
    1. Kaye SB, Kaufman B, Lubinski J, et al. Phase II open label, randomized, multicentre study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor to pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372–379.
    1. Ledermann JA, Harter P, Gourley C, et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) [ASCO abstract 5003] J Clin Oncol. 2011;29(S):5003.
    1. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2 multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–861.
    1. Abbott A trial of ABT-888 in combination with Temozolomide versus pegylated liposomal doxorubicin alone in ovarian cancer Bethesda, MD: US National Library of Medicine; 2011[updated August 26, 2011]. Available from: NLM identifier: NCT01170650. Accessed December 20, 2012

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere